Education
About Us
Working with TipRanks
Follow Us
Lyra Therapeutics, Inc. (LYRA)
:LYRA
LYRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.10 - $5.77
Previous CloseN/A
Volume832.93K
Average Volume (3M)1.09M
Market Cap
$7.95M
Enterprise Value$520.38K
Total Cash (Recent Filing)-$23.89M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.04
Next Earnings
May 13, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding65,880,140
10 Day Avg. Volume1,364,511
30 Day Avg. Volume1,093,345
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.52
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.34
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$2.00Price Target Upside1566.67% Upside
Rating ConsensusHold
Number of Analyst Covering2
---
Lyra Therapeutics News
PremiumCompany Announcements
Lyra Therapeutics Reports 2024 Financial Results and Updates
PremiumCompany Announcements
Lyra Therapeutics Pursues ENLIGHTEN 2 Trial for LYR-210
PremiumCompany Announcements
Lyra Therapeutics Restructures Board of Directors
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceLYRA reported EPS of $(0.18) versus consensus of $(0.22), showing better than expected financial performance.
Regulatory ProgressThe company received written responses from the FDA supporting a Type C meeting for LYR-210 development in CRSwNP patients.
Safety DataResults from the ENLIGHTEN 1 52-week extension study continue to support the safety of LYR-210.
Bears Say
Clinical Trial RisksENLIGHTEN I missed its primary endpoint, indicating increased risk for the ENLIGHTEN II readout.
Regulatory UncertaintyThere is a current lack of clarity around an approval path for LYR-210 and uncertainty around the outcome of the ENLIGHTEN II trial.
Stock Market ComplianceThe company announced plans to implement a reverse stock split to maintain compliance with NASDAQ listing standards.
---
Ownership Overview
9.11% Insiders
3.88% Mutual Funds
25.37% Other Institutional Investors
54.48% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
LYRA FAQ
What was Lyra Therapeutics, Inc.’s price range in the past 12 months?
Lyra Therapeutics, Inc. lowest stock price was $0.10 and its highest was $5.77 in the past 12 months.
What is Lyra Therapeutics, Inc.’s market cap?
Lyra Therapeutics, Inc.’s market cap is $7.95M.
When is Lyra Therapeutics, Inc.’s upcoming earnings report date?
Lyra Therapeutics, Inc.’s upcoming earnings report date is May 13, 2025 which is in 37 days.
How were Lyra Therapeutics, Inc.’s earnings last quarter?
Lyra Therapeutics, Inc. released its earnings results on Mar 13, 2025. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.12 by -$0.04.
Is Lyra Therapeutics, Inc. overvalued?
According to Wall Street analysts Lyra Therapeutics, Inc.’s price is currently Undervalued.
Does Lyra Therapeutics, Inc. pay dividends?
Lyra Therapeutics, Inc. does not currently pay dividends.
What is Lyra Therapeutics, Inc.’s EPS estimate?
Lyra Therapeutics, Inc.’s EPS estimate is -0.15.
How many shares outstanding does Lyra Therapeutics, Inc. have?
Lyra Therapeutics, Inc. has 65,880,140 shares outstanding.
What happened to Lyra Therapeutics, Inc.’s price movement after its last earnings report?
Lyra Therapeutics, Inc. reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.12. Following the earnings report the stock price went down -5.556%.
Which hedge fund is a major shareholder of Lyra Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LYRA
---
Company Description
Lyra Therapeutics, Inc.
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
---
LYRA Stock 12 Month Forecast
Average Price Target
$2.00
▲(1566.67% Upside)
Technical Analysis
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Vertex Pharmaceuticals
―
FibroGen
―
Crispr Therapeutics AG
―
---